The pivotal phase III ToGA (Trastuzumab for Gastric cancer) trial [27] showed that, in HER2 positive GCs, the addition of trastuzumab to standard platinum-based first line treatment was effective, with a median overall survival (mOS) of about 13.8 months in the experimental arm versus 11.1 in the standard one (HR: 0.74; p = 0.0046). Here, ERBB2 is linked to gastric cancer.